SAB Biotherapeutics (SABS) investor relations material

Transforming type 1 diabetes treatment

• Focuses on developing SAB-142, a fully human, multi-specific anti-thymocyte globulin (hATG) immunotherapy to delay onset and progression of type 1 diabetes (T1D) by modulating T cells and preserving C-peptide without immunosuppression.

• SAB-142 targets multiple immune cells, offering a better safety profile than rabbit ATG, with no serum sickness and low/no immunogenicity, enabling safe, chronic redosing.

• Early intervention with SAB-142 aims to preserve beta cell function, delay disease progression, and improve long-term outcomes for T1D patients.

Clinical validation and efficacy

• Phase 1 data showed encouraging C-peptide preservation and improved glycemic control in established T1D patients, with three out of four participants classified as super responders.

• SAB-142 demonstrated a sustained T-cell exhaustion signature, correlating with C-peptide preservation, and did not cause anti-drug antibodies or serum sickness.

• No sustained lymphodepletion or immunosuppression observed, supporting chronic redosing potential.

• Continuous glucose monitoring showed increased time in range from 73% to 85% at Day 120, with no increase in exogenous insulin use.

Market opportunity and regulatory pathway

• T1D represents a multi-billion dollar market with a global prevalence of ~9.5 million, expected to reach 14.7 million by 2040.

• SAB-142 is initially focused on newly diagnosed Stage 3 T1D (U.S. incidence of 64,000 annually), leveraging a regulatory pathway informed by Tzield.

• The proprietary Tc Bovine platform enables production of fully human, multi-specific polyclonal antibodies without human donors, creating high barriers to entry.